SNN

Smith & Nephew plc: 2005 Form 20-F Summary

Business Context and Reporting Period

Company: Smith & Nephew plc
Reporting Period: Fiscal year ended December 31, 2005
Business Overview: A global medical devices company operating in three primary segments: Orthopaedics (reconstruction, trauma, clinical therapies), Endoscopy (minimally invasive surgery), and Advanced Wound Management. The company operates in over 90 countries with significant revenue concentration in the United States (49% of 2005 revenue).
Accounting Standards: First-time adoption of International Financial Reporting Standards (IFRS) as adopted by the EU for the 2005 reporting period, replacing UK GAAP.

Key Financial Metrics (2005)

Note: All figures are in millions of Sterling (£) unless otherwise noted. Adjusted figures exclude restructuring, rationalisation, and specific one-time items.

Material Changes vs. Prior Period

• Revenue Growth: Reported revenue increased 13% to £1,407m. Underlying growth (excluding currency and acquisitions) was 11%. The US Dollar strengthened against Sterling, contributing a 2% favorable translation effect.
• Profitability: Operating profit rose 44% to £237m. This increase was driven by a £40m rise in trading profit and the absence of the £80m "macrotextured claim" charge recorded in 2004, partially offset by £47m in restructuring and rationalisation expenses.
• Segment Performance:
  • Orthopaedics: Revenue grew 19% to £698m, driven by a 21% increase in the sales force and strong growth in hip and knee reconstruction.
  • Endoscopy: Revenue grew 10% to £334m, with underlying growth of 8%.
  • Advanced Wound Management: Revenue grew 5% to £375m. Operating profit declined significantly due to a £39m charge for exiting tissue engineering operations.
• Discontinued Operations: The Group announced the sale of its 50% interest in the BSN Medical joint venture in December 2005 (completed February 2006). Results are classified as discontinued operations.

Guidance, Outlook, and Risks

• 2006 Outlook: Management expects high teens growth in trading profit. Orthopaedic trauma is expected to grow in the mid-teens, while reconstruction is expected to be slightly lower. Endoscopy growth is expected to improve to double digits. Advanced Wound Management growth is expected in mid-single digits, reducing to low-single digits after the tissue engineering exit.
• Currency Change: Effective January 2006, the Group changed its functional and reporting currency from Sterling to US Dollars to align with its principal business activities and reduce volatility.
• Key Risks:
  • Product Liability: Ongoing litigation regarding the macrotextured OXINIUM femoral knee components. A provision of £44m remains for pending and future claims, assuming no insurance recovery. Three insurers have declined coverage.
  • Regulatory: A US Attorney's subpoena regarding consulting agreements with surgeons is ongoing.
  • Market Competition: Highly competitive markets with significant competitors (e.g., Zimmer, Stryker, Johnson & Johnson).
• Dividends: A second interim dividend of 6.1¢ (approx. 3.5p for UK shareholders) was declared in February 2006, payable in May 2006.

Investor Verification Checklist

• Macrotextured Claim Provision: Verify the adequacy of the remaining £44m provision against the range of possible costs (£77m–£113m) and the status of insurance coverage disputes.
• BSN Medical Disposal: Confirm the final net proceeds and gain on disposal (estimated at $315m gain) to be recognized in 2006.
• Currency Impact: Assess the impact of the transition to US Dollar reporting on future comparability and the hedging strategy for the Sterling dividend component.
• Restructuring Costs: Monitor the cash outflow associated with the £47m restructuring charge, specifically the £39m tissue engineering exit and £8m endoscopy facility closure.
• Regulatory Subpoena: Track developments regarding the US Attorney's investigation into surgeon consulting agreements.